Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The approval came on the basis of two randomized clinical trials that had 177 adult and pediatric male patients with either ...

WEDNESDAY, April 2, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for ...

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or B, with or without inhibitors. Qfitlia offers less ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

"Today's approval of Qfitlia is significant for patients with hemophilia because it can be administered less frequently than other existing options," Tanya Wroblewski, M.D., deputy director of the ...

FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia By Lori Solomon HealthDay Reporter WEDNESDAY, April 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

WEDNESDAY, April 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...

WEDNESDAY, April 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Qfitlia (fitusiran ... 12 years of age and older with hemophilia A or hemophilia B, with or without ...